edarafone联合丁苯酞软胶囊治疗早期急性脑梗死患者的疗效及对神经元特异性烯醇化酶、S-100β蛋白和SOD水平的影响

中国基层医药 Pub Date : 2020-04-01 DOI:10.3760/CMA.J.ISSN.1008-6706.2020.07.023

Hong'e Wang, Lei Dong

引用次数: 0

摘要

Objective: To explore the efficacy of edaravone combined with butylphthalide soft capsules in the treatment of early acute cerebral infarction (ACI), and analyze the effects of this method on serum neuron specific enolase (NSE) and S-100 levels β The effects of protein and superoxide dismutase (SOD) levels. Method: 96 patients with acute cerebral infarction who were diagnosed and treated in the Department of Neurology at Linyi County People's Hospital from February 2017 to December 2018 were selected. They were randomly divided into an observation group and a control group, with 48 patients in each group. The control group was treated with edaravone alone, while the observation group was treated with a combination of butylphthalide soft capsules on the basis of the control group; Observe and analyze NSE and S-100 before and after treatment β、 Changes in SOD levels and scores on the National Institutes of Health Stroke Scale (NI-HSS). Result: Two groups of NSE and S-100 before treatment β There was no statistically significant difference in SOD levels (P>0.05); Serum NSE in the observation group after treatment (6.29 ± 1.72) μ G/L, S-100 β (3.73 ± 1.56) μ G/L, both lower than before treatment and lower than the control group (t=3.769, 3.317, all P<0.001); Post treatment observation group SOD (42.38 ± 7.32) μ G/L, significantly higher than the control group (t=3.533, P<0.05); The total effective treatment rate in the observation group was 97.92%, higher than 75.00% in the control group（ χ 2=10.766, P<0.001). Conclusion: The use of edaravone combined with butylphthalide soft capsules for the treatment of ACI can effectively improve the clinical treatment effect of ACI and further ensure the postoperative recovery of early acute cerebral infarction patients. It is worth promoting in the diagnosis and treatment of related diseases.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Effect of edarafone combined with butyphenphthalein soft capsule in the treatment of patients with early acute cerebral infarction and its influence on neuron-specific enolase, S-100β protein and SOD levels

目的探讨依达拉奉联合丁苯酞软胶囊治疗早期急性脑梗死(ACI)的疗效，分析该方法对血清神经元特异性烯醇化酶(NSE)、S-100β蛋白和超氧化物歧化酶(SOD)水平的影响。方法选择2017年2月至2018年12月临猗县人民医院神经内科诊疗的急性脑梗死患者96例，按照入院单双号随机标记法分为观察组和对照组各48例，对照组单独使用依达拉奉进行治疗，观察组患者在对照组的基础上联合丁苯酞软胶囊进行治疗；观察并分析治疗前后的NSE、S-100β、SOD水平变化以及美国国立卫生研究院卒中量表(NI-HSS)的评分变化。结果治疗前两组NSE、S-100β及SOD水平差异无统计学意义(P>0.05)；治疗后观察组血清NSE(6.29±1.72)μg/L、S-100β(3.73±1.56)μg/L，均低于治疗前，且均低于对照组(t＝3.769、3.317，均P<0.001)；治疗后观察组SOD(42.38±7.32)μg/L，明显高于对照组(t＝3.533，P<0.05)；观察组总有效治疗率为97.92%，高于对照组的75.00%(χ2＝10.766，P<0.001)。结论使用依达拉奉联合丁苯酞软胶囊进行对ACI进行治疗，可有效提高ACI的临床治疗效果，进一步保证早期急性脑梗死患者的术后恢复，值得在相关疾病诊治中推广。

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中国基层医药

CiteScore

0.10

自引率

0.00%

发文量

32251

期刊介绍： Since its inception, the journal "Chinese Primary Medicine" has adhered to the development strategy of "based in China, serving the grassroots, and facing the world" as its publishing concept, reporting a large amount of the latest medical information at home and abroad, prospering the academic field of primary medicine, and is praised by readers as a medical encyclopedia that updates knowledge. It is a core journal in China's medical and health field, and its influence index (CI) ranks Q2 in China's academic journals in 2022. It was included in the American Chemical Abstracts in 2008, the World Health Organization Western Pacific Regional Medical Index (WPRIM) in 2009, and the Japan Science and Technology Agency Database (JST) and Scopus Database in 2018, and was included in the Wanfang Data-China Digital Journal Group and the China Academic Journal Comprehensive Evaluation Database.